Morning Market Gainers

shares jumped 55.21 percent to $2.48. On Wednesday, the company reported final results from its TIVO-1 extension study.

shares climbed 33 percent to $2.70 after the company reported positive results of its OptimEyes trial for DME.

shares surged 29.38 percent to $4.00 after the company agreed to exclusive negotiations to be acquired by DHR International.

shares rose 25.55 percent to $3.40. The company will accelerate its Rexista(TM) Oxycodone XR development program on the basis of positive feedback from the United States Food and Drug Administration.

shares gained 24.44 percent to $13.50 after the company issued positive initial Phase I safety data for CB-839 in patients with acute leukemia.

shares rose 16.38 percent to $26.79. Youku reported a Q1 loss of $0.40 per share on non-GAAP sales of $170.4 million. Brean Capital maintained Buy rating on Youku Tudou and raised the price target from $20 to $26.

shares jumped 10.34 percent to $182.84. bluebird bio will present LentiGlobin clinical data on June 13, 2015 at the 20th Congress of European Hematology Association

rose 10.06 percent to $27.67 after the company reported stronger-than-expected earnings for the fiscal first quarter on Thursday.

shares climbed 4.80 percent to $35.40 after the company reported stronger-than-expected results for the first quarter on Thursday.

shares gained 4.76 percent to $73.50 after the company reported better-than-expected earnings for the first quarter and lifted its sales outlook for the full year.

shares gained 2.69 percent to $36.60 after the company reported better-than-expected earnings for the fiscal third quarter.

shares rose 1.22 percent to $95.78 session after

announced its plans to buy Omnicare for about $12.7 billion.